936 million people affected worldwide, a cardiovascular risk profile that complements traditional risk factors and new pharmacological treatment options: Current evidence from 2024-2026 paints a clearer picture of a link that has been underestimated for years. With around 936 million adults affected worldwide, obstructive sleep apnea (OSA) is one of the most common chronic diseases – and is still systematically overlooked in cardiology practice. Meta-analyses show an almost doubling of cardiovascular risk; in cardiology clinics, OSA is found in 40-80% of patients with hypertension, heart failure, coronary heart disease, atrial fibrillation or stroke. With the FDA approval of tirzepatide for OSA and obesity in December 2024 and current mechanistic data from the SURMOUNT OSA program, a new era of OSA therapy is beginning – with direct cardiological relevance.
Jetzt beitreten
